Skip to content

Change of Lung Function After Exercise in Patients With Chronic Obstructive Pulmonary Disease

Impact of Exercise on Lung Function in Patients With Chronic Obstructive Pulmonary Disease

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03551197
Enrollment
50
Registered
2018-06-11
Start date
2018-06-13
Completion date
2018-09-30
Last updated
2018-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exercise, Lung Function Decreased, Pulmonary Disease, Chronic Obstructive, Quality of Life

Keywords

Pulmonary Disease, Chronic Obstructive, exercise, lung function, quality of life

Brief summary

The purpose of this study is to evaluate the changes of lung function before and after the exercise in patients with chronic obstructive pulmonary disease.The assessment of quality of life is also carried out through questionnaires.

Detailed description

This is a randomized,open-label study to research the changes of lung function before and after exercise in patients with chronic obstructive pulmonary disease .At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),Clinical Chronic Obstructive Pulmonary Questionnaire(CCQ) and chronic obstructive pulmonary assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.

Interventions

DRUGBudesonide and formoterol bid

At baseline,lung function test,blood oxygen saturation and pulse are measured before and after 6-min walk test for each subject.Quality of life is assessed through questionnaires including modified Medical Research Council dyspnoea scale(mMRC),St George's Respiratory Questionnaire(SGRQ),clinical chronic obstructive pulmonary questionnaire(CCQ) and chronic obstructive pulmonary disease assessment test(CAT).And then budesonide(160ug) and formoterol(4.5ug) bid will be given to the subjects for 3 months.The subjects will have a follow-up visit with all the examinations mentioned above after 3 months' treatment.

Sponsors

Zhujiang Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

There is only one group.Patients with diagnosis of Chronic Obstructive Pulmonary Disease are recruited.Subjects will be examined at baseline and after 3 months' treatment of budesonide and formoterol.

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Male or female patients 18 to 80 years-old, inclusive. * A clinical diagnosis of chronic obstructive pulmonary disease according to the Global Initiative for Chronic Obstructive Disease(GOLD 2018) guidelines. * Post bronchodilator (following inhalation of salbutamol) forced expired volume in one second(FEV1)/forced vital capacity(FVC) ratio ≤0.70. * Willing and able to provide written informed consent. * Willing and able to attend all study visits and adhere to all study assessments and procedures.

Exclusion criteria

* Severe comorbidities including unstable cardiac or pulmonary disease or any other medical conditions including unstable ischemic heart disease,unstable cardiac arrhythmia or heart failure,life threatening arrhythmias,etc. * Recent history of chronic obstructive pulmonary disease exacerbation requiring hospitalization or need for increased treatments for chronic obstructive pulmonary disease within 6 weeks.

Design outcomes

Primary

MeasureTime frameDescription
Changes of forced expired volume in one second(FEV1) after 6-min walk test compared with resting stateAt resting state and after 6-min walk testForced expired volume in one second(FEV1) is measured by Jaeger MasterScreen Pulmonary Function Test System before and after 6-min walk test.

Secondary

MeasureTime frameDescription
Changes of inspiratory capacity(IC) after 6-min walk test compared with resting stateAt resting state and after 6-min walk testInspiratory capacity(IC) is measured by Jaeger MasterScreen Pulmonary Function Test System before and after 6-min walk test.
Changes of blood oxygen saturation after 6-min walk test compared with resting stateAt resting state and after 6-min walk testBlood oxygen saturation is measured before and after 6-min walk test.
Changes of pulse after 6-min walk test compared with resting stateAt resting state and after 6-min walk testPulse is measured before and after 6-min walk test.
Changes of forced expired volume in one second(FEV1) after 3 months' treatment compared with baselineChange from baseline to 3 monthsAt baseline,forced expired volume in one second(FEV1) is measured.After 3 months's treatment of budesonide and formoterol,FEV1 will be measured again.
Changes of inspiratory capacity(IC) after 3 months' treatment compared with baselineChange from baseline to 3 monthsAt baseline,inspiratory capacity(IC) is measured.After 3 months's treatment of budesonide and formoterol,IC will be measured again.
The distance and steps of 6-min walk testChange from baseline to 3 monthsBoth the the distance and steps are measured
Changes of impulse forced oscillometry parameters after 3 months' treatment compared with baselineChange from baseline to 3 monthsAt baseline,impulse forced oscillometry parameters are measured.After 3 months's treatment of budesonide and formoterol,impulse forced oscillometry parameters will be measured again.
Changes of modified Medical Research Council dyspnoea scale(mMRC) scores after 3 months' treatment compared with baselineChange from baseline to 3 monthsAt baseline,quality of life is assessed by modified Medical Research Council dyspnoea scale(mMRC).After 3 months's treatment of budesonide and formoterol,the mMRC scores will be measured again.
Changes of St George's Respiratory Questionnaire(SGRQ) scores after 3 months' treatment compared with baselineChange from baseline to 3 monthsAt baseline,quality of life is assessed by St George's Respiratory Questionnaire(SGRQ).After 3 months's treatment of budesonide and formoterol,the SGRQ scores will be measured again.
Changes of clinical chronic obstructive pulmonary questionnaire(CCQ) scores after 3 months' treatment compared with baselineChange from baseline to 3 monthsAt baseline,quality of life is assessed by clinical chronic obstructive pulmonary disease questionnaire(CCQ).After 3 months's treatment of budesonide and formoterol,the scores will be measured again.
Changes of chronic obstructive pulmonary disease assessment test(CAT) scores after 3 months' treatment compared with baselineChange from baseline to 3 monthsAt baseline,quality of life is assessed by chronic obstructive pulmonary disease assessment test(CAT).After 3 months's treatment of budesonide and formoterol,the test will be performed again.
Changes of diffusion function after 3 months' treatment compared with baselineChange from baseline to 3 monthsAt baseline,diffusion function is measured.After 3 months's treatment of budesonide and formoterol,diffusion function will be measured again.

Countries

China

Contacts

Primary ContactHuapeng Yu
359606545@qq.com+86 020-61643888

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026